CDC Level 2 Travel Health Notice: Malaria Spreading in Panama

What the notice says

On 17 November 2026, the U.S. Centers for Disease Control and Prevention issued a Level 2 (Practice Enhanced Precautions) travel health notice for malaria in Panama. The key change is geographic: increased cases are being reported in parts of the country that were previously classified as no-risk. Travelers who relied on older risk maps — or on prior trips to Panama where no precautions were advised — may therefore be working from outdated assumptions.

Malaria is transmitted by the bite of infected Anopheles mosquitoes, which feed mainly from dusk to dawn. Illness typically begins 7 days or more after an infective bite and can appear weeks to months after return. Reported symptoms commonly include fever, chills, headache, muscle aches, fatigue, nausea, and vomiting. Plasmodium falciparum infection can progress rapidly and is considered a medical emergency; some species can relapse long after travel.

General public-health guidance

CDC's standard advice for Level 2 malaria notices includes:

  • Consult a travel health provider ideally 4–6 weeks before departure to review itinerary-specific risk; some regimens must be started days to weeks before arrival.
  • Prevent bites: EPA-registered repellents (DEET, picaridin, IR3535, oil of lemon eucalyptus/PMD, 2-undecanone), permethrin-treated clothing and gear, long sleeves and trousers, air-conditioned or screened accommodation, and bed nets where appropriate.
  • Seek prompt medical care for fever during travel or for up to a year afterward, and tell the clinician about travel to Panama so malaria testing can be considered.

Why the "previously no-risk" detail matters

Risk classification drives both chemoprophylaxis decisions and clinical suspicion after return. Expanded transmission zones mean itineraries including cities, tourist corridors, or short-stay business travel may now warrant a formal risk assessment rather than being dismissed.

Pharmacist's note: As a pharmacist, my role here is informational, not prescriptive. Antimalarial selection depends on destination-specific resistance patterns, trip duration, pregnancy or breastfeeding status, hepatic and renal function, G6PD status for certain agents, psychiatric and seizure history, and — importantly — drug interactions. I frequently see conflicts with QT-prolonging medications, antacids and iron or calcium supplements that reduce absorption of some agents, warfarin, and hormonal contraceptives. Bring a complete medication list, including supplements, to your travel consultation. Also plan practically: verify you have enough supply for the full pre-travel, in-travel, and post-travel course, keep medicines in original labeled packaging, and check import rules for the countries you transit. Do not purchase antimalarials locally abroad without professional guidance; substandard and falsified products remain a documented problem in some markets.

Source: CDC Travel Health Notices — Level 2: Malaria in Panama (published 17 November 2026). Verify current status before departure, as notices are updated frequently.

Primary sources

PharmTrip may include promotional content. Products and services are independently evaluated by a licensed pharmacist and rankings are never altered by advertiser requests. Information reflects what was current at the time of writing — please verify the latest terms on each provider's official site.